U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
 2017 Scientific Symposium - EconoTimes)
PHILADELPHIA, April 04, 2017 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Adam Cuker, M.D., assistant professor of medicine at the Perelman School of Medicine of the University of Pennsylvania and a clinical investigator in the Phase 1/2 clinical trial of SPK-9001 for hemophilia B, will present updated interim data as of March 24, 2017 at the Hemostasis and Thrombosis Research Society (HTRS) 2017 Scientific Symposium in Scottsdale, Arizona.
The poster entitled “Initiation of Oral Steroid Therapy Produced Rapid Normalization of Transaminase Levels and Stabilization of FIX Activity in Subjects Who Developed Capsid-Directed T-Cell Responses in the SPK-9001: Adeno-Associated Virus-Mediated Gene Transfer for Hemophilia B Phase 1/2 Trial,” will be presented on Friday, April 7 from 5:15-6:15 p.m. MST.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations by the FDA, and access to the PRIority MEdicines (PRIME) Program by the EMA) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.
Investor Relations Contact: Ryan Asay [email protected] (215) 239-6424 Media Contact: Monique da Silva [email protected] (215) 282-7470
